# A CpG-methylation-based Assay for Stratifying Stage III Clear Cell Renal Cell Carcinoma of Receiving Adjuvant Treatment

> **NCT02688491** · NA · NOT_YET_RECRUITING · sponsor: **First Affiliated Hospital, Sun Yat-Sen University** · enrollment: 300 (estimated)

## Conditions studied

- Renal Neoplasms
- Targeted Molecular Therapy

## Interventions

- **DRUG:** sunitinib

## Key facts

- **NCT ID:** NCT02688491
- **Lead sponsor:** First Affiliated Hospital, Sun Yat-Sen University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2016-07
- **Primary completion:** 2026-07
- **Final completion:** 2026-07
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2016-02-25

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02688491

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02688491, "A CpG-methylation-based Assay for Stratifying Stage III Clear Cell Renal Cell Carcinoma of Receiving Adjuvant Treatment". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02688491. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*